Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
Launched by BIOMED INDUSTRIES, INC. · Sep 25, 2024
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and multiple-ascending doses in overweight/obese participants and as multiple doses in patients with Type 2 Diabetes Mellitus.
NA-931 is a Quadruple Receptor Agonist for Insulin Like Growth Factor 1 (IGF-1), Glucagon-like Peptide-1 (GLP-1), Gastric Inhibitory Polypeptide (GIP) and Glucagon.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants 18-65 years old, inclusive
- • BMI of 25 - 40, inclusive
- • Stable body weight for two months
- • Participants must be capable of giving signed informed consent
- • Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other clinical study procedures
- • Willing to comply with contraception requirements
- Exclusion Criteria:
- • History of significant medical conditions and malignancy
- • Uncontrollable hypertension
- • History of alcoholism or drug addiction within 1 year prior to Screening
- • Current or recent participation in an investigational clinical trial
- • Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion, or drug absorption
About Biomed Industries, Inc.
Biomed Industries, Inc. is a leading clinical trial sponsor dedicated to advancing medical research and development through innovative therapeutic solutions. With a strong focus on biopharmaceuticals, the company leverages cutting-edge technologies and rigorous scientific methodologies to design and execute clinical trials that prioritize patient safety and efficacy. Committed to collaboration and transparency, Biomed Industries partners with healthcare professionals and regulatory bodies to ensure compliance and accelerate the delivery of groundbreaking treatments to market. Their extensive expertise and dedication to quality make them a trusted partner in the clinical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Camperdown, New South Wales, Australia
Parkville, Victoria, Australia
Patients applied
Trial Officials
Lloyd Tran, PhD
Study Director
Biomed Industries, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported